138 related articles for article (PubMed ID: 36362189)
1. The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines.
Bollmann LM; Skerhut AJ; Asfaha Y; Horstick N; Hanenberg H; Hamacher A; Kurz T; Kassack MU
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362189
[TBL] [Abstract][Full Text] [Related]
2. 5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib.
Asfaha Y; Bollmann LM; Skerhut AJ; Fischer F; Horstick N; Roth D; Wecker M; Mammen C; Smits SHJ; Fluegen G; Kassack MU; Kurz T
Eur J Med Chem; 2024 Jan; 263():115907. PubMed ID: 37979441
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells.
Schrenk C; Bollmann LM; Haist C; Bister A; Wiek C; Wecker M; Roth D; Petzsch P; Köhrer K; Hamacher A; Hanenberg H; Fluegen G; Kassack MU
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982651
[TBL] [Abstract][Full Text] [Related]
4. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
5. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
6. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
[TBL] [Abstract][Full Text] [Related]
8. Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells.
Nie D; Huang K; Yin S; Li Y; Xie S; Ma L; Wang X; Wu Y; Xiao J
Leuk Lymphoma; 2012 Dec; 53(12):2487-95. PubMed ID: 22642934
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.
Steinwascher S; Nugues AL; Schoeneberger H; Fulda S
Cancer Lett; 2015 Sep; 366(1):32-43. PubMed ID: 26028172
[TBL] [Abstract][Full Text] [Related]
11. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
Xu X; Xie C; Edwards H; Zhou H; Buck SA; Ge Y
PLoS One; 2011 Feb; 6(2):e17138. PubMed ID: 21359182
[TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
Alves Avelar LA; Schrenk C; Sönnichsen M; Hamacher A; Hansen FK; Schliehe-Diecks J; Borkhardt A; Bhatia S; Kassack MU; Kurz T
Eur J Med Chem; 2021 Feb; 211():113095. PubMed ID: 33360560
[TBL] [Abstract][Full Text] [Related]
15. FOXO3a Activation by HDAC Class IIa Inhibition Induces Cell Cycle Arrest in Pancreatic Cancer Cells.
Usami M; Kikuchi S; Takada K; Ono M; Sugama Y; Arihara Y; Hayasaka N; Nakamura H; Ikeda Y; Hirakawa M; Yoshida M; Miyanishi K; Kobune M; Kato J
Pancreas; 2020 Jan; 49(1):135-142. PubMed ID: 31856089
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Fuchs O; Provaznikova D; Marinov I; Kuzelova K; Spicka I
Cardiovasc Hematol Disord Drug Targets; 2009 Mar; 9(1):62-77. PubMed ID: 19275578
[TBL] [Abstract][Full Text] [Related]
17. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Miller CP; Rudra S; Keating MJ; Wierda WG; Palladino M; Chandra J
Blood; 2009 Apr; 113(18):4289-99. PubMed ID: 19182209
[TBL] [Abstract][Full Text] [Related]
18. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]